Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Etoposide in High-Risk Adrenocortical Carcinoma
NCT03723941Phase 3Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jul 2018
- Primary completion
- Feb 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) and etoposide in adrenocortical carcinoma (ACC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Recurrence-Free Survival at 36 months. Started Jul 2018; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)etoposide
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT03723941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723941.